399 related articles for article (PubMed ID: 17721094)
1. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
[TBL] [Abstract][Full Text] [Related]
2. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
3. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
[TBL] [Abstract][Full Text] [Related]
4. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
5. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.
Lundgren JD; Mocroft A; Gatell JM; Ledergerber B; D'Arminio Monforte A; Hermans P; Goebel FD; Blaxhult A; Kirk O; Phillips AN;
J Infect Dis; 2002 Jan; 185(2):178-87. PubMed ID: 11807691
[TBL] [Abstract][Full Text] [Related]
6. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
[TBL] [Abstract][Full Text] [Related]
7. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
[TBL] [Abstract][Full Text] [Related]
8. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
Podlekareva D; Mocroft A; Kirk O; Reiss P; Aldins P; Katlama C; Kovari H; Stellbrink HJ; D'Arminio Monforte A; Lundgren JD;
Scand J Infect Dis; 2008; 40(11-12):908-13. PubMed ID: 18609197
[TBL] [Abstract][Full Text] [Related]
9. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
Reekie J; Mocroft A; Sambatakou H; Machala L; Chiesi A; van Lunzen J; Clumeck N; Kirk O; Gazzard B; Lundgren JD;
AIDS; 2008 Nov; 22(17):2381-90. PubMed ID: 18981778
[TBL] [Abstract][Full Text] [Related]
10. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
[TBL] [Abstract][Full Text] [Related]
11. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
12. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
[TBL] [Abstract][Full Text] [Related]
13. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
[TBL] [Abstract][Full Text] [Related]
14. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
[TBL] [Abstract][Full Text] [Related]
16. Anemia and survival in human immunodeficiency virus.
Lundgren JD; Mocroft A
Clin Infect Dis; 2003; 37 Suppl 4():S297-303. PubMed ID: 14581998
[TBL] [Abstract][Full Text] [Related]
17. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.
Costello C; Nelson KE; Suriyanon V; Sennun S; Tovanabutra S; Heilig CM; Shiboski S; Jamieson DJ; Robison V; Rungruenthanakit K; Duerr A
Int J Epidemiol; 2005 Jun; 34(3):577-84. PubMed ID: 15737969
[TBL] [Abstract][Full Text] [Related]
19. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
[TBL] [Abstract][Full Text] [Related]
20. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
Mocroft A; Kirk O; Clumeck N; Gargalianos-Kakolyris P; Trocha H; Chentsova N; Antunes F; Stellbrink HJ; Phillips AN; Lundgren JD
Cancer; 2004 Jun; 100(12):2644-54. PubMed ID: 15197808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]